The award recognizes the discovery of the fin-loop in glutathione peroxidase 4 (GPX4), a short protein segment that anchors the enzyme in a nerve cell membrane and helps eliminate lipid peroxides that could damage it. Marcus Conrad likened GPX4 to a surfboard: with the fin in the water, it glides along the membrane's inner surface, detoxifying as it moves. Children inheriting the R152H mutation in GPX4 have a board that can no longer catch the wave. Although the enzyme remains present and retains its catalytic ability in laboratory tests, it becomes ineffective when it matters most.

This key structural insight clarified a decade of confusion. It reveals why an enzyme appearing normal in activity assays can cause severe disease, especially affecting neurons with polyunsaturated fatty acid-rich membranes. Additionally, it underscores why ferroptosis, once considered merely a lab curiosity, is now recognized as a significant factor in human neurodegeneration. The research was published in Cell in 2026 and took nearly fourteen years, according to Marcus Conrad.

For the SSMD community, the consequences were immediate and practical. A mechanism now exists to describe: a mutation-specific stem cell and organoid system that mimics the disease, a mouse with the same variant, and a way to test candidate drugs.

Research in Partnership with Affected Families

The Raghav Prize was created for work that could not have happened without patients and families. The three American children whose shared R152H variant started the investigation were found through a family-built network. Skin cells from an affected child were reprogrammed into stem cells and grown into cortical neurons and brain organoids. Parents raised money, kept a registry, chased the sequencing data, and enabled a biobank. CureGPX4's founder, Sanath, is a co-author on the paper, which is where a patient organization belongs when it has done that much of the work.

“When Raghav was diagnosed, we were told there was nothing to work with. No mechanism, no model, no drug, no trial, and a prognosis delivered in a tone that suggested we should stop asking,” said Sanath Kumar Ramesh, founder of the CureGPX4 Foundation. “Marcus and his team spent fourteen years turning that nothing into a structure you can point at on a screen. Plenty of scientists have been kind to my family. Marcus was kind, took our calls, sent us the cells back, and then went and solved it.”

“We named the prize after our son because we want the field to remember who the work is for,” Ramesh added. “Raghav is not a case report. He is the reason this Science exists.”

About the Raghav Prize

The Raghav Prize will be awarded annually to a researcher whose work has materially changed the outlook for an ultra-rare disease and who did that work in partnership with the affected community.

Laureates are asked to do one thing beyond accepting: spend a day with the families of the disease community, in person or online, answering whatever they want to ask, at whatever level of detail they want it. Marcus Conrad has agreed and has proposed that his co-first authors come too.

“Prizes in this business usually come from committees of people who look like me,” said Marcus Conrad. “This one comes from the families who sent us their children's cells and then waited for many years without ever asking us to hurry. It is the one I will keep on the desk rather than the shelf.”

About Sedaghatian-Type Spondylometaphyseal Dysplasia

Sedaghatian-type spondylometaphyseal dysplasia (SSMD) is an ultra-rare autosomal recessive disorder caused by mutations in GPX4. Most affected infants die within days of birth from respiratory failure. The small number who survive live with profound developmental delay, feeding and hearing difficulties, skeletal abnormalities, seizures, and progressive neurodegeneration. Fewer than a dozen children are known to be living with the condition worldwide.
 

The digital platform is now available at gesund-mit-ki.de (German only). It presents concrete, everyday scenarios across five stages of life. How might intelligent wearables support Clara, 34, and her unborn child throughout pregnancy in 2036? How could AI help diagnose the rare condition of 16-year-old Lena? How might it save the life of Sebastian, 55, after a stroke? And how will assistive robots support older people in need of care ten years from now?

Each story is based on the expertise of researchers at the Technical University of Munich (TUM), Ludwig Maximilian University (LMU), and Helmholtz Munich, and reflects the current state of research. In addition to these patient stories, the researchers also address broader questions such as: “Will people with serious illnesses increasingly be filtered out before birth?” and “How will drugs be developed in the years ahead?”.

Content Developed Through Dialogue

A distinctive feature of the platform is that many of the topics were developed in advance in workshops with members of the public. The aim is to help a broad audience better understand the potential, limitations, and societal implications of AI applications. The project has already been presented at the “Festival of the Future,” and additional public events are planned.

The M1 partners – TUM, LMU and their university hospitals, as well as Helmholtz Munich – are collaborating on the project with Wort & Bild Verlag (including apotheken-umschau.de).

Further Information and Links

M1 – Munich Medicine Alliance was established to promote cutting-edge medical research and the translation of scientific findings into patient care. Its members include the Technical University of Munich (TUM), Ludwig Maximilian University of Munich (LMU) and its university hospitals, as well as Helmholtz Munich.

Science Year 2026 – Medicine of the Future

clever.gesund